Product

Glucagon Nasal Powder

Aliases

Baqsimi, Glucagon Nasal Powder [Baqsimi], LY900018

Name

Baqsimi

INN Name

glucagon

FDA Approved

Yes

1 clinical trial

2 organizations

1 indication

1 document

Indication

Type 1 Diabetes

Clinical trial

An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years

Status: Completed, Estimated PCD: 2023-11-03

Document

DailyMed Label: Baqsimi

Organization

Eli Lilly and Company

Organization

Amphastar Pharmaceuticals, Inc.